What's Happening?
BeneMeat Technologies is actively selling cultivated mammalian cells as a notified feed material in the European Union, specifically for use in dog food. Their product, Coolty Meat, a wet dog food from Forza10 containing 26% cultivated meat, recently
won the Pet Food & Nutrition category of the Fi Europe Innovation Awards. This approach allows BeneMeat to generate revenue from its cultivated meat technology without waiting for the lengthier approval process required for human consumption. The company's Prague plant is designed to produce 400 to 600 kg of cultivated meat daily. Forza10 is currently piloting Coolty Meat with retailers in Spain and Portugal, with plans for expansion into more European countries by 2027. While the product is being sold, the specific production cost per kilo of BeneMeat cells and the ingredient's shelf price in the pilot markets have not been publicly disclosed.
Why It's Important?
This development is significant as it demonstrates a viable, albeit indirect, market entry strategy for cultivated meat companies in the EU. By targeting the pet food industry, BeneMeat Technologies can establish a revenue stream and gather valuable production and market data while the regulatory landscape for human-grade cultivated meat continues to evolve. This strategy could provide a blueprint for other cultivated meat startups facing similar regulatory hurdles, allowing them to scale production and refine their processes. The success of Coolty Meat in the pet food market could also build consumer acceptance and familiarity with cultivated meat products, potentially easing the transition to human consumption in the future. However, the lack of public cost data makes it difficult to assess the economic viability and scalability of this approach in the long term, particularly concerning its potential impact on the broader food industry.
What's Next?
Forza10 plans to expand the pilot program for Coolty Meat to more European countries by 2027, which will provide further insights into market acceptance and repeat purchase rates. The open question for BeneMeat Technologies remains the cost per kilo of its cultivated cells and whether the Iberian pilot demonstrates profitability at a price that covers production expenses. The company's current strategy allows it to earn revenue and collect data, which could be crucial for future investment and expansion into the human food market once regulatory approvals are secured. Other cultivated meat companies may observe BeneMeat's 'feed route' as a potential model for early commercialization and revenue generation, especially given the ongoing and often lengthy regulatory processes for human food applications in various regions.
Beyond the Headlines
The use of cultivated cells in pet food raises interesting ethical and legal considerations. While it provides a pathway for commercialization, it also highlights the differing regulatory standards between animal feed and human food. This could lead to discussions about the appropriate classification and oversight of cultivated products, particularly as the technology advances. Furthermore, the success of cultivated meat in the pet food sector could influence public perception and acceptance of lab-grown proteins. If consumers become comfortable with the idea of their pets consuming cultivated meat, it might reduce skepticism surrounding its eventual introduction into the human diet. This strategy also underscores the innovative ways companies are navigating complex regulatory environments to bring novel food technologies to market, potentially accelerating the development and adoption of sustainable protein alternatives.













